APO Research
Talk to an analyst

APO RESEARCH · REPORT

Innovations in Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Innovations in Biologics and Biosimilars Market Outlook and Growth Opportunities 2026

21 December 2025200 pages

Choose your research edition.

Industry ResearchInnovations in Biologics and Biosimilars Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Innovations in Biologics and Biosimilars Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Innovations in Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Innovations in Biologics and Biosimilars Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Innovations in Biologics and Biosimilars Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Innovations in Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Innovations in Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Innovations in Biologics and Biosimilars market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Innovations in Biologics and Biosimilars market include Changchun High Tech, Tonghua Dongbao, Sobi, Sanofi, Johnson & Johnson, Novartis, Novo Nordisk, Merck and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Innovations in Biologics and Biosimilars market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Innovations in Biologics and Biosimilars and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Innovations in Biologics and Biosimilars revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Innovations in Biologics and Biosimilars market.

Innovations in Biologics and Biosimilars Segment by Company

Changchun High Tech

Tonghua Dongbao

Sobi

Sanofi

Johnson & Johnson

Novartis

Novo Nordisk

Merck

Roche

Eli Lilly

Pfizer

Kanghong Pharma

Biogen

Amgen

AbbVie

United Laboratory

Innovent Biologics

Gan&Lee

Celltrion

3SBIO

Innovations in Biologics and Biosimilars Segment by Type

Vaccines

Insulin

Interferon

Monoclonal Antibodies

Others

Innovations in Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Innovations in Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Innovations in Biologics and Biosimilars status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Innovations in Biologics and Biosimilars key companies, revenue, market share, and recent developments.

3. To split the Innovations in Biologics and Biosimilars breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Innovations in Biologics and Biosimilars market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Innovations in Biologics and Biosimilars significant trends, drivers, influence factors in global and regions.

6. To analyze Innovations in Biologics and Biosimilars competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Innovations in Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Innovations in Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Innovations in Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Innovations in Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Innovations in Biologics and Biosimilars company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Innovations in Biologics and Biosimilars in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Innovations in Biologics and Biosimilars in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Innovations in Biologics and Biosimilars Industry Trends Table 2. Innovations in Biologics and Biosimilars Industry Drivers Table 3. Innovations in Biologics and Biosimilars Industry Opportunities and Challenges Table 4. Innovations in Biologics and Biosimilars Industry Restraints Table 5. Global Innovations in Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Innovations in Biologics and Biosimilars Revenue Share by Company (2021-2026) Table 7. Global Innovations in Biologics and Biosimilars Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Innovations in Biologics and Biosimilars Key Company Manufacturing Base & Headquarters Table 9. Global Innovations in Biologics and Biosimilars Company, Product Type & Application Table 10. Global Innovations in Biologics and Biosimilars Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Innovations in Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Vaccines Table 15. Significant Companies of Insulin Table 16. Significant Companies of Interferon Table 17. Significant Companies of Monoclonal Antibodies Table 18. Significant Companies of Others Table 19. Global Innovations in Biologics and Biosimilars Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Innovations in Biologics and Biosimilars Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Innovations in Biologics and Biosimilars Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Innovations in Biologics and Biosimilars Sales Value Share by Type (2021-2026) Table 23. Global Innovations in Biologics and Biosimilars Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospital Table 25. Significant Companies of Retail Pharmacy Table 26. Significant Companies of Other Table 27. Global Innovations in Biologics and Biosimilars Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Innovations in Biologics and Biosimilars Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Innovations in Biologics and Biosimilars Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Innovations in Biologics and Biosimilars Sales Value Share by Application (2021-2026) Table 31. Global Innovations in Biologics and Biosimilars Sales Value Share by Application (2027-2032) Table 32. Global Innovations in Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Innovations in Biologics and Biosimilars Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Innovations in Biologics and Biosimilars Sales Value Share by Region (2021-2026) Table 35. Global Innovations in Biologics and Biosimilars Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Innovations in Biologics and Biosimilars Sales Value Share by Region (2027-2032) Table 37. Global Innovations in Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Innovations in Biologics and Biosimilars Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Innovations in Biologics and Biosimilars Sales Value Market Share by Country (2021-2026) Table 40. Global Innovations in Biologics and Biosimilars Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Innovations in Biologics and Biosimilars Sales Value Market Share by Country (2027-2032) Table 42. Changchun High Tech Company Information Table 43. Changchun High Tech Business Overview Table 44. Changchun High Tech Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Changchun High Tech Innovations in Biologics and Biosimilars Product Portfolio Table 46. Changchun High Tech Recent Development Table 47. Tonghua Dongbao Company Information Table 48. Tonghua Dongbao Business Overview Table 49. Tonghua Dongbao Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Tonghua Dongbao Innovations in Biologics and Biosimilars Product Portfolio Table 51. Tonghua Dongbao Recent Development Table 52. Sobi Company Information Table 53. Sobi Business Overview Table 54. Sobi Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Sobi Innovations in Biologics and Biosimilars Product Portfolio Table 56. Sobi Recent Development Table 57. Sanofi Company Information Table 58. Sanofi Business Overview Table 59. Sanofi Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Sanofi Innovations in Biologics and Biosimilars Product Portfolio Table 61. Sanofi Recent Development Table 62. Johnson & Johnson Company Information Table 63. Johnson & Johnson Business Overview Table 64. Johnson & Johnson Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Johnson & Johnson Innovations in Biologics and Biosimilars Product Portfolio Table 66. Johnson & Johnson Recent Development Table 67. Novartis Company Information Table 68. Novartis Business Overview Table 69. Novartis Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Novartis Innovations in Biologics and Biosimilars Product Portfolio Table 71. Novartis Recent Development Table 72. Novo Nordisk Company Information Table 73. Novo Nordisk Business Overview Table 74. Novo Nordisk Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Novo Nordisk Innovations in Biologics and Biosimilars Product Portfolio Table 76. Novo Nordisk Recent Development Table 77. Merck Company Information Table 78. Merck Business Overview Table 79. Merck Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Merck Innovations in Biologics and Biosimilars Product Portfolio Table 81. Merck Recent Development Table 82. Roche Company Information Table 83. Roche Business Overview Table 84. Roche Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Roche Innovations in Biologics and Biosimilars Product Portfolio Table 86. Roche Recent Development Table 87. Eli Lilly Company Information Table 88. Eli Lilly Business Overview Table 89. Eli Lilly Innovations in Biologics and Biosimilars Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Eli Lilly Innovations in Biologics and Biosimilars Product Portfolio Table 91. Eli Lilly Recent Development Table 92. Pfizer Company Information Table 93. Pfizer Business Overview Table 94. Pfizer Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Pfizer Innovations in Biologics and Biosimilars Product Portfolio Table 96. Pfizer Recent Development Table 97. Kanghong Pharma Company Information Table 98. Kanghong Pharma Business Overview Table 99. Kanghong Pharma Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. Kanghong Pharma Innovations in Biologics and Biosimilars Product Portfolio Table 101. Kanghong Pharma Recent Development Table 102. Biogen Company Information Table 103. Biogen Business Overview Table 104. Biogen Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Biogen Innovations in Biologics and Biosimilars Product Portfolio Table 106. Biogen Recent Development Table 107. Amgen Company Information Table 108. Amgen Business Overview Table 109. Amgen Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Amgen Innovations in Biologics and Biosimilars Product Portfolio Table 111. Amgen Recent Development Table 112. AbbVie Company Information Table 113. AbbVie Business Overview Table 114. AbbVie Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. AbbVie Innovations in Biologics and Biosimilars Product Portfolio Table 116. AbbVie Recent Development Table 117. United Laboratory Company Information Table 118. United Laboratory Business Overview Table 119. United Laboratory Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. United Laboratory Innovations in Biologics and Biosimilars Product Portfolio Table 121. United Laboratory Recent Development Table 122. Innovent Biologics Company Information Table 123. Innovent Biologics Business Overview Table 124. Innovent Biologics Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. Innovent Biologics Innovations in Biologics and Biosimilars Product Portfolio Table 126. Innovent Biologics Recent Development Table 127. Gan&Lee Company Information Table 128. Gan&Lee Business Overview Table 129. Gan&Lee Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Gan&Lee Innovations in Biologics and Biosimilars Product Portfolio Table 131. Gan&Lee Recent Development Table 132. Celltrion Company Information Table 133. Celltrion Business Overview Table 134. Celltrion Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Celltrion Innovations in Biologics and Biosimilars Product Portfolio Table 136. Celltrion Recent Development Table 137. 3SBIO Company Information Table 138. 3SBIO Business Overview Table 139. 3SBIO Innovations in Biologics and Biosimilars Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 140. 3SBIO Innovations in Biologics and Biosimilars Product Portfolio Table 141. 3SBIO Recent Development Table 142. Research Programs/Design for This Report Table 143. Authors List of This Report Table 144. Secondary Sources Table 145. Primary Sources List of Figures Figure 1. Innovations in Biologics and Biosimilars Product Image Figure 2. Global Innovations in Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Innovations in Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 4. Global Innovations in Biologics and Biosimilars Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Vaccines Image Figure 8. Insulin Image Figure 9. Interferon Image Figure 10. Monoclonal Antibodies Image Figure 11. Others Image Figure 12. Global Innovations in Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Innovations in Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Innovations in Biologics and Biosimilars Sales Value Share by Type (2021-2032) Figure 15. Hospital Image Figure 16. Retail Pharmacy Image Figure 17. Other Image Figure 18. Global Innovations in Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Innovations in Biologics and Biosimilars Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Innovations in Biologics and Biosimilars Sales Value Share by Application (2021-2032) Figure 21. Global Innovations in Biologics and Biosimilars Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Innovations in Biologics and Biosimilars Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Innovations in Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 24. North America Innovations in Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Innovations in Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Innovations in Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Innovations in Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Innovations in Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Innovations in Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 30. South America Innovations in Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Innovations in Biologics and Biosimilars Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Innovations in Biologics and Biosimilars Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccines
  • Insulin
  • Interferon
  • Monoclonal Antibodies
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Changchun High Tech
  • Tonghua Dongbao
  • Sobi
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Novo Nordisk
  • Merck
  • Roche
  • Eli Lilly
  • Pfizer
  • Kanghong Pharma
  • Biogen
  • Amgen
  • AbbVie
  • United Laboratory
  • Innovent Biologics
  • Gan&Lee
  • Celltrion
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Innovations in Biologics and Biosimilars Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Innovations in Biologics and Biosimilars Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Innovations in Biologics and Biosimilars Market Dynamics
  1. 2.1 Innovations in Biologics and Biosimilars Industry Trends
  2. 2.2 Innovations in Biologics and Biosimilars Industry Drivers
  3. 2.3 Innovations in Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Innovations in Biologics and Biosimilars Industry Restraints
3 Innovations in Biologics and Biosimilars Market by Company
  1. 3.1 Global Innovations in Biologics and Biosimilars Company Revenue Ranking in 2025
  2. 3.2 Global Innovations in Biologics and Biosimilars Revenue by Company (2021-2026)
  3. 3.3 Global Innovations in Biologics and Biosimilars Company Ranking (2024-2026)
  4. 3.4 Global Innovations in Biologics and Biosimilars Company Manufacturing Base and Headquarters
  5. 3.5 Global Innovations in Biologics and Biosimilars Company Product Type and Application
  6. 3.6 Global Innovations in Biologics and Biosimilars Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Innovations in Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Innovations in Biologics and Biosimilars Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Innovations in Biologics and Biosimilars Market by Type
  1. 4.1 Innovations in Biologics and Biosimilars Type Introduction
  2. 4.1.1 Vaccines
  3. 4.1.2 Insulin
  4. 4.1.3 Interferon
  5. 4.1.4 Monoclonal Antibodies
  6. 4.1.5 Others
  7. 4.2 Global Innovations in Biologics and Biosimilars Sales Value by Type
  8. 4.2.1 Global Innovations in Biologics and Biosimilars Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Innovations in Biologics and Biosimilars Sales Value by Type (2021-2032)
  10. 4.2.3 Global Innovations in Biologics and Biosimilars Sales Value Share by Type (2021-2032)
5 Innovations in Biologics and Biosimilars Market by Application
  1. 5.1 Innovations in Biologics and Biosimilars Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Innovations in Biologics and Biosimilars Sales Value by Application
  6. 5.2.1 Global Innovations in Biologics and Biosimilars Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Innovations in Biologics and Biosimilars Sales Value by Application (2021-2032)
  8. 5.2.3 Global Innovations in Biologics and Biosimilars Sales Value Share by Application (2021-2032)
6 Innovations in Biologics and Biosimilars Regional Value Analysis
  1. 6.1 Global Innovations in Biologics and Biosimilars Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Innovations in Biologics and Biosimilars Sales Value by Region (2021-2032)
  3. 6.2.1 Global Innovations in Biologics and Biosimilars Sales Value by Region: 2021-2026
  4. 6.2.2 Global Innovations in Biologics and Biosimilars Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Innovations in Biologics and Biosimilars Sales Value (2021-2032)
  7. 6.3.2 North America Innovations in Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Innovations in Biologics and Biosimilars Sales Value (2021-2032)
  10. 6.4.2 Europe Innovations in Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Innovations in Biologics and Biosimilars Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Innovations in Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Innovations in Biologics and Biosimilars Sales Value (2021-2032)
  16. 6.6.2 South America Innovations in Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Innovations in Biologics and Biosimilars Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Innovations in Biologics and Biosimilars Sales Value Share by Country, 2025 VS 2032
7 Innovations in Biologics and Biosimilars Country-level Value Analysis
  1. 7.1 Global Innovations in Biologics and Biosimilars Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Innovations in Biologics and Biosimilars Sales Value by Country (2021-2032)
  3. 7.2.1 Global Innovations in Biologics and Biosimilars Sales Value by Country (2021-2026)
  4. 7.2.2 Global Innovations in Biologics and Biosimilars Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Innovations in Biologics and Biosimilars Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Innovations in Biologics and Biosimilars Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Innovations in Biologics and Biosimilars Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Changchun High Tech
  2. 8.1.1 Changchun High Tech Company Information
  3. 8.1.2 Changchun High Tech Business Overview
  4. 8.1.3 Changchun High Tech Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Changchun High Tech Innovations in Biologics and Biosimilars Product Portfolio
  6. 8.1.5 Changchun High Tech Recent Developments
  7. 8.2 Tonghua Dongbao
  8. 8.2.1 Tonghua Dongbao Company Information
  9. 8.2.2 Tonghua Dongbao Business Overview
  10. 8.2.3 Tonghua Dongbao Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tonghua Dongbao Innovations in Biologics and Biosimilars Product Portfolio
  12. 8.2.5 Tonghua Dongbao Recent Developments
  13. 8.3 Sobi
  14. 8.3.1 Sobi Company Information
  15. 8.3.2 Sobi Business Overview
  16. 8.3.3 Sobi Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sobi Innovations in Biologics and Biosimilars Product Portfolio
  18. 8.3.5 Sobi Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Innovations in Biologics and Biosimilars Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Johnson & Johnson
  26. 8.5.1 Johnson & Johnson Company Information
  27. 8.5.2 Johnson & Johnson Business Overview
  28. 8.5.3 Johnson & Johnson Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Johnson & Johnson Innovations in Biologics and Biosimilars Product Portfolio
  30. 8.5.5 Johnson & Johnson Recent Developments
  31. 8.6 Novartis
  32. 8.6.1 Novartis Company Information
  33. 8.6.2 Novartis Business Overview
  34. 8.6.3 Novartis Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Novartis Innovations in Biologics and Biosimilars Product Portfolio
  36. 8.6.5 Novartis Recent Developments
  37. 8.7 Novo Nordisk
  38. 8.7.1 Novo Nordisk Company Information
  39. 8.7.2 Novo Nordisk Business Overview
  40. 8.7.3 Novo Nordisk Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novo Nordisk Innovations in Biologics and Biosimilars Product Portfolio
  42. 8.7.5 Novo Nordisk Recent Developments
  43. 8.8 Merck
  44. 8.8.1 Merck Company Information
  45. 8.8.2 Merck Business Overview
  46. 8.8.3 Merck Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Merck Innovations in Biologics and Biosimilars Product Portfolio
  48. 8.8.5 Merck Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Innovations in Biologics and Biosimilars Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Eli Lilly
  56. 8.10.1 Eli Lilly Company Information
  57. 8.10.2 Eli Lilly Business Overview
  58. 8.10.3 Eli Lilly Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Eli Lilly Innovations in Biologics and Biosimilars Product Portfolio
  60. 8.10.5 Eli Lilly Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Innovations in Biologics and Biosimilars Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Kanghong Pharma
  68. 8.12.1 Kanghong Pharma Company Information
  69. 8.12.2 Kanghong Pharma Business Overview
  70. 8.12.3 Kanghong Pharma Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Kanghong Pharma Innovations in Biologics and Biosimilars Product Portfolio
  72. 8.12.5 Kanghong Pharma Recent Developments
  73. 8.13 Biogen
  74. 8.13.1 Biogen Company Information
  75. 8.13.2 Biogen Business Overview
  76. 8.13.3 Biogen Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biogen Innovations in Biologics and Biosimilars Product Portfolio
  78. 8.13.5 Biogen Recent Developments
  79. 8.14 Amgen
  80. 8.14.1 Amgen Company Information
  81. 8.14.2 Amgen Business Overview
  82. 8.14.3 Amgen Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Amgen Innovations in Biologics and Biosimilars Product Portfolio
  84. 8.14.5 Amgen Recent Developments
  85. 8.15 AbbVie
  86. 8.15.1 AbbVie Company Information
  87. 8.15.2 AbbVie Business Overview
  88. 8.15.3 AbbVie Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AbbVie Innovations in Biologics and Biosimilars Product Portfolio
  90. 8.15.5 AbbVie Recent Developments
  91. 8.16 United Laboratory
  92. 8.16.1 United Laboratory Company Information
  93. 8.16.2 United Laboratory Business Overview
  94. 8.16.3 United Laboratory Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  95. 8.16.4 United Laboratory Innovations in Biologics and Biosimilars Product Portfolio
  96. 8.16.5 United Laboratory Recent Developments
  97. 8.17 Innovent Biologics
  98. 8.17.1 Innovent Biologics Company Information
  99. 8.17.2 Innovent Biologics Business Overview
  100. 8.17.3 Innovent Biologics Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Innovent Biologics Innovations in Biologics and Biosimilars Product Portfolio
  102. 8.17.5 Innovent Biologics Recent Developments
  103. 8.18 Gan&Lee
  104. 8.18.1 Gan&Lee Company Information
  105. 8.18.2 Gan&Lee Business Overview
  106. 8.18.3 Gan&Lee Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Gan&Lee Innovations in Biologics and Biosimilars Product Portfolio
  108. 8.18.5 Gan&Lee Recent Developments
  109. 8.19 Celltrion
  110. 8.19.1 Celltrion Company Information
  111. 8.19.2 Celltrion Business Overview
  112. 8.19.3 Celltrion Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Celltrion Innovations in Biologics and Biosimilars Product Portfolio
  114. 8.19.5 Celltrion Recent Developments
  115. 8.20 3SBIO
  116. 8.20.1 3SBIO Company Information
  117. 8.20.2 3SBIO Business Overview
  118. 8.20.3 3SBIO Innovations in Biologics and Biosimilars Revenue and Gross Margin (2021-2026)
  119. 8.20.4 3SBIO Innovations in Biologics and Biosimilars Product Portfolio
  120. 8.20.5 3SBIO Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst